From Name:
From Email:
To Name:
To Email:

Optional Message:


Antiangiogenic agents in ovarian cancer

from OncLive (Video interview)

Bevacizumab is an antiangiogenic agent that exploits the tumor microvasculature, explains Robert A. Burger, MD. As long as there is no disease progression or unacceptable toxicities, and patients are willing to receive it, bevacizumab therapy should be continued indefinitely, states James Tate Thigpen, MD. Burger notes that there are studies in non-gynecologic tumors, such as colon cancer, that have continued antiangiogenic therapy beyond disease progression and demonstrated survival advantage in the next line of therapy. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063